Home > Riviste > Italian Journal of Dermatology and Venereology > Fascicoli precedenti > Giornale Italiano di Dermatologia e Venereologia 2020 October;155(5) > Giornale Italiano di Dermatologia e Venereologia 2020 October;155(5):537-41



Opzioni di pubblicazione
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo



Giornale Italiano di Dermatologia e Venereologia 2020 October;155(5):537-41

DOI: 10.23736/S0392-0488.19.06524-6


lingua: Inglese

Blau Syndrome: NOD2-related systemic autoinflammatory granulomatosis

Sanami TAKADA 1, Megumu K. SAITO 2, Naotomo KAMBE 3

1 Laboratory for Immunology, Department of Pediatrics, Leiden University Medical Center, Leiden, the Netherlands; 2 Department of Clinical Application, Center for iPS cell Research and Application, Kyoto University, Kyoto, Japan; 3 Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan

Blau Syndrome, or early-onset sarcoidosis, is hereditary juvenile-onset systemic granulomatosis. Clinical symptoms appear before the age of four years and mainly affect the skin, joints, and eyes. The symptoms are progressive and cause severe complications, such as joint destruction and blindness. Although tumor necrosis factor alpha (TNFα) antagonists are effective for controlling some of the symptoms of Blau Syndrome, there is no specific curative treatment. Heterozygous mutations in nucleotide-binding oligomerization domain 2 (NOD2) were identified as the cause of Blau Syndrome onset. NOD2 is an intracellular pathogen recognition receptor, the ligand of which is muramyl dipeptide (MDP) found in bacterial cell walls. Upon binding to MDP, NOD2 activates the NF-κB pathway, which leads to upregulation of proinflammatory cytokines. However, the detailed molecular mechanisms by which disease associated NOD2 mutations lead to autoinflammation and granuloma formation are still unclear. To clarify the relationship between disease associated NOD2 mutations and the inflammatory response, we established induced pluripotent stem (iPS) cells from Blau Syndrome patients. Functional analyses using these iPS cells suggested that IFNγ is a critical mediator of the inflammatory manifestations in this disease. This experimental finding is supported by the clinical observation that bacillus Calmette-Guesrin (BCG) vaccination is sometimes associated with disease onset, since IFNγ is a major cytokine associated with BCG-mediated immune responses. Further investigation of NOD2 signaling and accumulation of clinical cases are essential to elucidate the mechanisms of Blau Syndrome and develop an effective treatment for patients.

KEY WORDS: Uveitis; NOD2 protein, human; Blau Syndrome

inizio pagina